BofA Sees Double-Digit Upside in Definitive Healthcare Corp. (DH)

Definitive Healthcare Corp. (NASDAQ:DH) is among the best US stocks under $10 to invest in. BofA Securities has reaffirmed its Buy rating on Definitive Healthcare Corp. (NASDAQ:DH), while maintaining a price target of $4.50, implying a surge of 16.3%. This move comes as the company reports revenue and EBITDA above the research firm’s estimates and consensus forecasts.

In its latest earnings call, Definitive Healthcare Corp. (NASDAQ:DH) has raised full-year revenue guidance to $237-$240 million owing to better retention. This signals the company’s focus on streamlining its sales force. The management also announced the addition of 12 new enterprise clients within the quarter.

The company’s future looks promising, with analysts emphasizing retention rates, renewal trends, and the impact of operational changes. With strong initiatives in mind, Definitive Healthcare Corp. (NASDAQ:DH) is poised for growth.

Definitive Healthcare Corp. (NASDAQ:DH), headquartered in Massachusetts, is a provider of a SaaS healthcare commercial intelligence platform. Founded in 2011, the company has a well-diversified clientele in the biopharmaceutical, healthcare, and technology industries.

While we acknowledge the potential of DH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.